Skip to main content
Fig. 1 | Critical Care

Fig. 1

From: Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem

Fig. 1

Participant and analysis population flow chart. CE Clinically evaluable, C/T Ceftolozane/tazobactam, ITT Intention-to-treat, ME Microbiologically evaluable, mITT Microbiologic intention-to-treat, N Number of participants in specific analysis population

Back to article page

Critical Care

ISSN: 1364-8535